X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Pfizer with Piramal Healthcare - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PFIZER vs PIRAMAL ENTERPRISES - Comparison Results

PFIZER    Change

Pfizer India is a 71% subsidiary of the world's largest pharmaceuticals company Pfizer Inc. Pfizer derives a larger share of its revenues from the pharmaceuticals division (81%). The company also has presence in the animal health (13%) and clinical d... More

PIRAMAL ENTERPRISES 
   Change

Piramal Enterprises has a presence in custom manufacturing, critical care OTC and financial services. To give a boost to its custom manufacturing operations, the company had acquired Avecia Pharmaceuticals, UK in 2005 and Pfizer's Morpeth facility in... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PFIZER PIRAMAL ENTERPRISES PFIZER/
PIRAMAL ENTERPRISES
 
P/E (TTM) x 27.5 39.0 70.6% View Chart
P/BV x 4.4 3.2 135.0% View Chart
Dividend Yield % 0.7 0.8 98.6%  

Financials

 PFIZER   PIRAMAL ENTERPRISES
EQUITY SHARE DATA
    PFIZER
Mar-16
PIRAMAL ENTERPRISES
Mar-17
PFIZER/
PIRAMAL ENTERPRISES
5-Yr Chart
Click to enlarge
High Rs2,7242,095 130.0%   
Low Rs1,6111,025 157.2%   
Sales per share (Unadj.) Rs440.9492.8 89.5%  
Earnings per share (Unadj.) Rs48.772.6 67.1%  
Cash flow per share (Unadj.) Rs75.894.7 80.0%  
Dividends per share (Unadj.) Rs15.0021.00 71.4%  
Dividend yield (eoy) %0.71.3 51.4%  
Book value per share (Unadj.) Rs462.9862.5 53.7%  
Shares outstanding (eoy) m45.75172.56 26.5%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.93.2 155.3%   
Avg P/E ratio x44.521.5 207.0%  
P/CF ratio (eoy) x28.616.5 173.6%  
Price / Book Value ratio x4.71.8 258.8%  
Dividend payout %30.828.9 106.4%   
Avg Mkt Cap Rs m99,163269,194 36.8%   
No. of employees `0002.94.0 72.0%   
Total wages/salary Rs m2,75817,939 15.4%   
Avg. sales/employee Rs Th6,981.721,190.3 32.9%   
Avg. wages/employee Rs Th954.54,470.1 21.4%   
Avg. net profit/employee Rs Th771.13,120.0 24.7%   
INCOME DATA
Net Sales Rs m20,17085,037 23.7%  
Other income Rs m8572,338 36.7%   
Total revenues Rs m21,02887,374 24.1%   
Gross profit Rs m4,31034,991 12.3%  
Depreciation Rs m1,2393,817 32.5%   
Interest Rs m520,310 0.0%   
Profit before tax Rs m3,92313,202 29.7%   
Minority Interest Rs m01,699 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m99-100 -99.4%   
Tax Rs m1,7942,281 78.7%   
Profit after tax Rs m2,22812,520 17.8%  
Gross profit margin %21.441.1 51.9%  
Effective tax rate %45.717.3 264.7%   
Net profit margin %11.014.7 75.0%  
BALANCE SHEET DATA
Current assets Rs m16,29987,590 18.6%   
Current liabilities Rs m7,594185,578 4.1%   
Net working cap to sales %43.2-115.2 -37.5%  
Current ratio x2.10.5 454.7%  
Inventory Days Days6531 210.3%  
Debtors Days Days2648 54.2%  
Net fixed assets Rs m8,622108,523 7.9%   
Share capital Rs m458345 132.6%   
"Free" reserves Rs m20,722148,481 14.0%   
Net worth Rs m21,180148,826 14.2%   
Long term debt Rs m25144,957 0.0%   
Total assets Rs m29,137482,394 6.0%  
Interest coverage x755.51.7 45,785.7%   
Debt to equity ratio x01.0 0.1%  
Sales to assets ratio x0.70.2 392.7%   
Return on assets %7.76.8 112.6%  
Return on equity %10.58.4 125.0%  
Return on capital %19.012.0 158.9%  
Exports to sales %0.10-   
Imports to sales %17.50-   
Exports (fob) Rs m12NA-   
Imports (cif) Rs m3,526NA-   
Fx inflow Rs m5215,001 0.3%   
Fx outflow Rs m1405,150 2.7%   
Net fx Rs m-889,851 -0.9%   
CASH FLOW
From Operations Rs m3,436-100,393 -3.4%  
From Investments Rs m-6,991-24,202 28.9%  
From Financial Activity Rs m-619135,705 -0.5%  
Net Cashflow Rs m-4,17411,110 -37.6%  

Share Holding

Indian Promoters % 0.0 52.9 -  
Foreign collaborators % 63.9 0.0 -  
Indian inst/Mut Fund % 7.5 4.0 187.5%  
FIIs % 4.9 26.6 18.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 23.7 16.5 143.6%  
Shareholders   85,207 93,274 91.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PFIZER With:   CADILA HEALTHCARE  TTK HEALTHCARE  SHASUN PHARMA  BIOCON LTD  J.B.CHEMICALS  

Compare PFIZER With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Of Crash in Bitcoin, Correction in MidCap and SmallCap Indices and Top Stocks in Action Today(Pre-Open)

The past year has seen the BSE MidCap and BSE SmallCap indices surging by 43.1% and 57.1% respectively. Taking a two year view these indices have produced mind-boggling return of 75.3% .

Related Views on News

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

Is it Wise to Ignore Bitcoins?(The 5 Minute Wrapup)

Jan 4, 2018

While investing in bitcoins, it would make sense to treat it as another asset class and decide accordingly.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Resolutions for 2018 - by others(The Honest Truth)

Jan 8, 2018

Ten quirky new year resolutions. Guess by whom?

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PFIZER SHARE PRICE


Jan 16, 2018 (Close)

TRACK PFIZER

PFIZER - GSK PHARMA COMPARISON

COMPARE PFIZER WITH

MARKET STATS